D. E. Shaw & Co. Inc. Buys 1,442,799 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

D. E. Shaw & Co. Inc. grew its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 26.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,824,517 shares of the biotechnology company’s stock after buying an additional 1,442,799 shares during the quarter. D. E. Shaw & Co. Inc. owned 2.94% of ADMA Biologics worth $76,298,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in shares of ADMA Biologics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock worth $7,398,000 after buying an additional 27,357 shares in the last quarter. Principal Financial Group Inc. lifted its stake in ADMA Biologics by 17.7% in the fourth quarter. Principal Financial Group Inc. now owns 158,634 shares of the biotechnology company’s stock worth $717,000 after acquiring an additional 23,844 shares during the period. Eagle Asset Management Inc. grew its holdings in ADMA Biologics by 20.2% during the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 4,367 shares in the last quarter. Alberta Investment Management Corp increased its position in ADMA Biologics by 32.4% during the 4th quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock valued at $2,083,000 after purchasing an additional 112,831 shares during the period. Finally, Campbell & CO Investment Adviser LLC raised its holdings in shares of ADMA Biologics by 19.2% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 143,424 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 23,127 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 0.3 %

Shares of NASDAQ ADMA opened at $19.44 on Friday. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $20.16. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The company’s 50-day simple moving average is $16.27 and its 200-day simple moving average is $11.30. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -972.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) earnings per share. Equities analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright boosted their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Mizuho increased their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.50.

Insiders Place Their Bets

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the sale, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jerrold B. Grossman sold 136,861 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the sale, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.